Descriptor English: | Dactinomycin | ||||||
Descriptor Spanish: |
Dactinomicina
| ||||||
Descriptor Portuguese: | Dactinomicina | ||||||
Descriptor French: | Dactinomycine | ||||||
Entry term(s): |
Actinomycin Actinomycin D Cosmegen Cosmegen Lyovac Lyovac Cosmegen Lyovac, Cosmegen Lyovac-Cosmegen LyovacCosmegen Meractinomycin |
||||||
Tree number(s): |
D03.633.300.200 D04.345.566.252 D12.644.641.252 |
||||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D003609 | ||||||
Scope note: | A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) |
||||||
Allowable Qualifiers: |
AA analogs & derivatives AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BI biosynthesis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis EC economics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UR urine |
||||||
Pharm Action: |
Anti-Bacterial Agents Antibiotics, Antineoplastic Protein Synthesis Inhibitors Nucleic Acid Synthesis Inhibitors |
||||||
Registry Number: | 1CC1JFE158 | ||||||
CAS Type 1 Name: | Actinomycin D | ||||||
Public MeSH Note: | 66; ACTINOMYCIN was heading 1963-95 |
||||||
History Note: | 66; ACTINOMYCIN was heading 1963-95 |
||||||
DeCS ID: | 3628 | ||||||
Unique ID: | D003609 | ||||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||||
Date Established: | 1966/01/01 | ||||||
Date of Entry: | 1999/01/01 | ||||||
Revision Date: | 2017/05/24 |
-
-
CHEMICALS AND DRUGS
Heterocyclic Compounds [D03]Heterocyclic Compounds -
CHEMICALS AND DRUGS
Polycyclic Compounds [D04]Polycyclic Compounds -
CHEMICALS AND DRUGS
Amino Acids, Peptides, and Proteins [D12]Amino Acids, Peptides, and Proteins
|
Dactinomycin
- Preferred
Actinomycin
- Broader
Cosmegen
- Narrower
Concept UI |
M0005644 |
Scope note | A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) |
Preferred term | Dactinomycin |
Entry term(s) |
Actinomycin D Meractinomycin |
Concept UI |
M0005643 |
Preferred term | Actinomycin |
Concept UI |
M0354002 |
Preferred term | Cosmegen |
Entry term(s) |
Cosmegen Lyovac Lyovac Cosmegen Lyovac, Cosmegen Lyovac-Cosmegen LyovacCosmegen |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey